General Information of Drug Transporter (DT)
DT ID DTD0007 Transporter Info
Gene Name SLC47A1
Transporter Name Multidrug and toxin extrusion protein 1
Gene ID
55244
UniProt ID
Q96FL8
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Ranitidine Approved Drug
DT Modulation Ranitidine inhibits the transportation of Metformin by SLC47A1 (IC50 = 18.9 microM) [1]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
DT Modulation Ranitidine inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 17.5 microM) [1]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
DT Modulation Ranitidine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 25.4 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Ranitidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Quinine Approved Drug
DT Modulation Quinine inhibits the transportation of 1-methyl-4-phenylpyridinium by SLC47A1 (IC50 = 1.9 microM) [4]
Affected Drug/Substrate 1-methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-MATE1
DT Modulation Quinine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 29.2 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Quinine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Ritonavir Approved Drug
DT Modulation Ritonavir inhibits the transportation of Metformin by SLC47A1 (IC50 = 15.4 microM) [1]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
DT Modulation Ritonavir inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 13.9 microM) [1]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
DT Modulation Ritonavir inhibits the activity of SLC47A1 (IC50 = 3.1 microM) [5]
Exogenous Factor Chloroquine Approved Drug
DT Modulation Chloroquine inhibits the transportation of Metformin by SLC47A1 (IC50 = 2.5 microM) [6]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Chloroquine inhibits the activity of SLC47A1 [6]
Exogenous Factor Cimetidine Approved Drug
DT Modulation Cimetidine inhibits the transportation of Metformin by SLC47A1 (Ki = 3.8 microM) [7]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Cimetidine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 1.1 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Mitoxantrone Approved Drug
DT Modulation Mitoxantrone inhibits the transportation of Metformin by SLC47A1 (IC50 = 4.4 microM) [1]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
DT Modulation Mitoxantrone inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 5.2 microM) [1]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
Exogenous Factor Rapamycin Approved Drug
DT Modulation Rapamycin inhibits the transportation of Metformin by SLC47A1 (IC50 = 3.27 microM) [1]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
DT Modulation Rapamycin inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 3.51 microM) [1]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-MATE1
Exogenous Factor Amantadine Approved Drug
DT Modulation Amantadine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 111.8 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Amantadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Cetirizine Approved Drug
DT Modulation Cetirizine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 371.2 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Cetirizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Metformin Approved Drug
DT Modulation Metformin inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 666.9 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Metformin modulates the activity of SLC47A1 [11]
Exogenous Factor Cigarette smoke condensate Natural Product
DT Modulation Cigarette smoke condensate inhibits the transportation of Verapamil by repressing mRNA expression of SLC47A1 (IC50 = 6.1 microM) [8]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-MATE1
DT Modulation Cigarette smoke condensate inhibits the activity of SLC47A1 (IC50 = 6.1 microM) [10]
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Carvedilol Approved Drug
DT Modulation Carvedilol inhibits the activity of SLC47A1 (IC50 = 103 microM) [9]
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
DT Modulation Carvedilol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor DX-619 Discontinued Drug
DT Modulation DX-619 inhibits the transportation of Creatinine by SLC47A1 (Ki = 0.82 microM) [12]
Affected Drug/Substrate Creatinine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Famotidine Approved Drug
DT Modulation Famotidine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 0.6 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Diltiazem Approved Drug
DT Modulation Diltiazem inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 12.5 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Verapamil Approved Drug
DT Modulation Verapamil inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 27.5 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Imipramine Approved Drug
DT Modulation Imipramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 42 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Desipramine Approved Drug
DT Modulation Desipramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 55.7 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Talipexole Drug in Phase 4 Trial
DT Modulation Talipexole inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 66 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Disopyramide Approved Drug
DT Modulation Disopyramide inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 83.8 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Diphenhydramine Approved Drug
DT Modulation Diphenhydramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 87 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Chlorpheniramine Approved Drug
DT Modulation Chlorpheniramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 87.6 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Pramipexole Approved Drug
DT Modulation Pramipexole inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 141.4 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Procainamide Approved Drug
DT Modulation Procainamide inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 217 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Tetramethrin Natural Product
DT Modulation Tetramethrin inhibits the transportation of Verapamil by SLC47A1 (IC50 = 47.5 microM) [13]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Allethrin Natural Product
DT Modulation Allethrin inhibits the transportation of Verapamil by SLC47A1 (IC50 = 50.2 microM) [13]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Isorhamnetin Natural Product
DT Modulation Isorhamnetin inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 0.32 microM) [14]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Exogenous Factor Telaprevir Approved Drug
DT Modulation Telaprevir inhibits the activity of SLC47A1 (IC50 = 0.023 microM) [15]
Exogenous Factor Cobicistat Approved Drug
DT Modulation Cobicistat inhibits the activity of SLC47A1 (IC50 = 4.4 microM) [5]
Exogenous Factor Azacitidine Approved Drug
DT Modulation Azacitidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Buspirone Approved Drug
DT Modulation Buspirone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Chlorhexidine Approved Drug
DT Modulation Chlorhexidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Ciclopirox Approved Drug
DT Modulation Ciclopirox inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Clonidine Approved Drug
DT Modulation Clonidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Cortisone Approved Drug
DT Modulation Cortisone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Dexamethasone Approved Drug
DT Modulation Dexamethasone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Diclofenac Approved Drug
DT Modulation Diclofenac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Dihydroergotamine Approved Drug
DT Modulation Dihydroergotamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Domperidone Approved Drug
DT Modulation Domperidone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Enalapril Approved Drug
DT Modulation Enalapril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Epinastine Approved Drug
DT Modulation Epinastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Erythromycin Approved Drug
DT Modulation Erythromycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Ethinyl estradiol Approved Drug
DT Modulation Ethinyl estradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Furosemide Approved Drug
DT Modulation Furosemide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Gabexate Approved Drug
DT Modulation Gabexate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Granisetron Approved Drug
DT Modulation Granisetron inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Indomethacin Approved Drug
DT Modulation Indomethacin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Irbesartan Approved Drug
DT Modulation Irbesartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Irinotecan Approved Drug
DT Modulation Irinotecan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Levofloxacin Approved Drug
DT Modulation Levofloxacin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Lidocaine Approved Drug
DT Modulation Lidocaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Losartan Approved Drug
DT Modulation Losartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Methylergonovine Approved Drug
DT Modulation Methylergonovine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Prazosin Approved Drug
DT Modulation Prazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Rimantadine Approved Drug
DT Modulation Rimantadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Spironolactone Approved Drug
DT Modulation Spironolactone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Sulfacetamide Approved Drug
DT Modulation Sulfacetamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Sumatriptan Approved Drug
DT Modulation Sumatriptan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Telmisartan Approved Drug
DT Modulation Telmisartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Thiabendazole Approved Drug
DT Modulation Thiabendazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Topotecan Approved Drug
DT Modulation Topotecan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Tubocurarine Approved Drug
DT Modulation Tubocurarine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Zafirlukast Approved Drug
DT Modulation Zafirlukast inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Crizotinib Approved Drug
DT Modulation Crizotinib inhibits the transportation of Creatinine by SLC47A1 [16]
Affected Drug/Substrate Creatinine Modulation Type Inhibition
Cell System MATE1-overexpressing cells
Exogenous Factor Astemizole Drug Withdrawn
DT Modulation Astemizole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Bithionol Drug Withdrawn
DT Modulation Bithionol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Camostat Drug in Phase 2 Trial
DT Modulation Camostat inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor CB3304 Drug in Phase 1/2 Trial
DT Modulation CB3304 inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Phenacetin Drug Withdrawn
DT Modulation Phenacetin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Green tea Natural Product
DT Modulation Green tea inhibits the transportation of Metformin by SLC47A1 [17]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MATE1
Exogenous Factor Epigallocatechin gallate Natural Product
DT Modulation Epigallocatechin gallate inhibits the transportation of Metformin by SLC47A1 [17]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE1
Exogenous Factor Itraconazole Approved Drug
DT Modulation Itraconazole inhibits the activity of SLC47A1 [18]
Exogenous Factor Ketoconazole Approved Drug
DT Modulation Ketoconazole inhibits the activity of SLC47A1 [18]
Exogenous Factor Plazomicin Approved Drug
DT Modulation Plazomicin inhibits the activity of SLC47A1 [19]
Exogenous Factor Trimethoprim Approved Drug
DT Modulation Trimethoprim inhibits the activity of SLC47A1 [6]
References
1 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
2 Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009 Apr;329(1):185-91.
3 Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013 Feb 14;56(3):781-795.
4 Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther. 2012 Jun;341(3):743-55.
5 No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat. J Pharm Sci. 2019 Apr 26. pii: S0022-3549(19)30289-8.
6 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
7 Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012 Feb;340(2):393-403.
8 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
9 Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res. 2018 Sep 6;35(11):204.
10 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
11 Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701.
12 Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011 Jan;89(1):81-8.
13 Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
14 Components of foods inhibit a drug exporter, human multidrug and toxin extrusion transporter 1. Biol Pharm Bull. 2014;37(2):292-7.
15 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
16 Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Sci Rep. 2018 Jun 18;8(1):9237.
17 Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
18 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
19 No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Jan 3.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.